MedDataX Logo

Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.

NCT ID: NCT06025227

Last Updated: 2025-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Provide pre-approval single patient Expanded Access (Compassionate Use) of Etrasimod for patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

NCT06294925

Colitis, Ulcerative
RECRUITING

Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

NCT04607837

Ulcerative Colitis
COMPLETED PHASE2

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232

Ulcerative Colitis
ACTIVE_NOT_RECRUITING PHASE3

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

NCT02447302

Ulcerative Colitis
COMPLETED PHASE2

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626

Colitis, Ulcerative
RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colitis, Ulcerative

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etrasimod

tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient must be intolerant, have a contraindication or had inadequate response to at least 3 therapies available for Ulcerative Colitis (UC) in this country or provide a rationale of why therapy was not used.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

PfizerCares

Role: CONTACT

[email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C504

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126 RECRUITING PHASE2
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
NCT06521762 WITHDRAWN PHASE2
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
NCT02100696 COMPLETED PHASE3
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797 COMPLETED PHASE2
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03945188 COMPLETED PHASE3
A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT04176588 ACTIVE_NOT_RECRUITING PHASE3
Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
NCT07243639 RECRUITING NA
Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
NCT05061446 COMPLETED PHASE2
An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease
NCT03362736 NO_LONGER_AVAILABLE
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
NCT03996369 COMPLETED PHASE3
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
NCT02249078 WITHDRAWN PHASE1
Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment
NCT06867042 NOT_YET_RECRUITING PHASE2
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis
NCT00729872 COMPLETED PHASE1/PHASE2
Expanded Access to Risankizumab
NCT03914261 NO_LONGER_AVAILABLE
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis
NCT01461317 COMPLETED PHASE2
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
NCT03808103 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
NCT03100864 COMPLETED PHASE2
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis
NCT01620255 COMPLETED PHASE2
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
NCT01221818 COMPLETED PHASE1
Fecal Microbiota Transplantation in Patients With Ulcerative Colitis
NCT01961492 WITHDRAWN NA
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
NCT00269841 COMPLETED PHASE3
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
NCT00787202 COMPLETED PHASE2
PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial
NCT06301477 ACTIVE_NOT_RECRUITING NA
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06049017 ACTIVE_NOT_RECRUITING PHASE2
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
NCT02136069 COMPLETED PHASE3